These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34703536)

  • 21. Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin.
    Ni D; Liu D; Zhang J; Lu S
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29300353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight.
    Sharma J; Bhardwaj V; Purohit R
    ACS Omega; 2019 Oct; 4(14):15815-15823. PubMed ID: 31592171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
    Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
    J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
    Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
    Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation.
    Bian X; Dong W; Zhao Y; Sun R; Kong W; Li Y
    J Mol Model; 2014 Apr; 20(4):2166. PubMed ID: 24633771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation.
    Liu X; Yang S; Hart JR; Xu Y; Zou X; Zhang H; Zhou Q; Xia T; Zhang Y; Yang D; Wang MW; Vogt PK
    Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
    Barlaam B; Cosulich S; Delouvrié B; Ellston R; Fitzek M; Germain H; Green S; Hancox U; Harris CS; Hudson K; Lambert-van der Brempt C; Lebraud H; Magnien F; Lamorlette M; Le Griffon A; Morgentin R; Ouvry G; Page K; Pasquet G; Polanska U; Ruston L; Saleh T; Vautier M; Ward L
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5155-62. PubMed ID: 26475521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.
    Ranjbar R; Mohammadpour S; Torshizi Esfahani A; Namazian S; Yaghob-Taleghani M; Baghaei K; Mortazavi Tabatabaei SA; Pasharavesh L; Nazemalhosseini-Mojarad E
    Gastroenterol Hepatol Bed Bench; 2019; 12(Suppl1):S22-S29. PubMed ID: 32099598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PI3Kα is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart.
    McLean BA; Zhabyeyev P; Patel VB; Basu R; Parajuli N; DesAulniers J; Murray AG; Kassiri Z; Vanhaesebroeck B; Oudit GY
    Cardiovasc Res; 2015 Mar; 105(3):292-303. PubMed ID: 25618408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
    Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
    Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of PI3Kα (Phosphoinositide 3-Kinase Alpha) Inhibition on Hemostasis and Thrombosis.
    Laurent PA; Hechler B; Solinhac R; Ragab A; Cabou C; Anquetil T; Severin S; Denis CV; Mangin PH; Vanhaesebroeck B; Payrastre B; Gratacap MP
    Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):2041-2053. PubMed ID: 30354258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors.
    Liu C; Cao Y; Zuo Y; Zhang C; Ren S; Zhang X; Wang C; Zeng Y; Ling J; Liu Y; Chen Z; Cao X; Wu Z; Zhang C; Lu J
    J Adv Res; 2024 Mar; ():. PubMed ID: 38471647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of molecular recognition of phosphoinositide-3-kinase α inhibitor through molecular dynamics simulation.
    Li Y; Zhang J; He D; Liang Q; Wang Y
    J Mol Model; 2012 May; 18(5):1907-16. PubMed ID: 21870199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural basis of nSH2 regulation and lipid binding in PI3Kα.
    Miller MS; Schmidt-Kittler O; Bolduc DM; Brower ET; Chaves-Moreira D; Allaire M; Kinzler KW; Jennings IG; Thompson PE; Cole PA; Amzel LM; Vogelstein B; Gabelli SB
    Oncotarget; 2014 Jul; 5(14):5198-208. PubMed ID: 25105564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-Molecule Study Reveals How Receptor and Ras Synergistically Activate PI3Kα and PIP
    Buckles TC; Ziemba BP; Masson GR; Williams RL; Falke JJ
    Biophys J; 2017 Dec; 113(11):2396-2405. PubMed ID: 29211993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced cardiac PI3Kα signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure.
    Yang KC; Jay PY; McMullen JR; Nerbonne JM
    Cardiovasc Res; 2012 Feb; 93(2):252-62. PubMed ID: 22038742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel potential PI3Kα inhibitors for cancer therapy.
    Zhang Q; Sang F; Qian J; Lyu S; Wang W; Wang Y; Li Q; Du L
    J Biomol Struct Dyn; 2021 Jul; 39(10):3721-3732. PubMed ID: 32425109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Preexisting Rare
    Romano G; Chen PL; Song P; McQuade JL; Liang RJ; Liu M; Roh W; Duose DY; Carapeto FCL; Li J; Teh JLF; Aplin AE; Chen M; Zhang J; Lazar AJ; Davies MA; Futreal PA; Amaria RN; Zhang DY; Wargo JA; Kwong LN
    Cancer Discov; 2018 May; 8(5):556-567. PubMed ID: 29496665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.